Shore Capital Reaffirms Hold Rating for Vectura Group (VEC)

Vectura Group (LON:VEC)‘s stock had its “hold” rating reiterated by equities researchers at Shore Capital in a research note issued to investors on Monday.

A number of other research analysts also recently commented on the company. Peel Hunt reduced their price target on Vectura Group from GBX 160 ($2.21) to GBX 120 ($1.66) and set a “hold” rating for the company in a report on Wednesday, February 14th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Vectura Group in a report on Thursday, January 25th. Numis Securities reissued a “buy” rating and issued a GBX 170 ($2.35) price target on shares of Vectura Group in a report on Thursday, January 4th. Finally, Royal Bank of Canada raised Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) price target for the company in a report on Thursday, December 14th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of GBX 169.56 ($2.34).

Shares of Vectura Group (LON:VEC) traded down GBX 1.85 ($0.03) on Monday, reaching GBX 79.50 ($1.10). The company had a trading volume of 6,202,302 shares, compared to its average volume of 4,610,000. Vectura Group has a 1 year low of GBX 70 ($0.97) and a 1 year high of GBX 166.97 ($2.31).

TRADEMARK VIOLATION WARNING: “Shore Capital Reaffirms Hold Rating for Vectura Group (VEC)” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at

Vectura Group Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with's FREE daily email newsletter.

Leave a Reply